Trials / Completed
CompletedNCT06626464
A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)
A Phase 1 Clinical Study to Evaluate the Absorption, Metabolism and Excretion of [14C]MK-8189 in Healthy Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to learn what happens to elpipodect in a healthy person's body over time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]Elpipodect | Oral administration |
Timeline
- Start date
- 2022-05-13
- Primary completion
- 2022-07-08
- Completion
- 2022-07-08
- First posted
- 2024-10-03
- Last updated
- 2026-04-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06626464. Inclusion in this directory is not an endorsement.